The OncFive: Top Oncology Articles for the Week of 12/18
Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.
Related Articles
AACR Distinguished Lectureship recipient offers insight into invasive lobular carcinoma research – SABCS Meeting News
Steffi Oesterreich, PhD, on Thursday shared highlights from her seminal fundamental and translational research on invasive lobular carcinoma.
How the 2024 elections can impact cancer policy – The Cancer Letter
As we come within a stone’s throw of Nov. 5, we can’t help but wonder if and how the election outcome will impact health care…
AACR Oncology Industry Partnering Event: From Cancer Discoveries to Patients
Discover emerging themes and early-stage clinical oncology pipelines at the second AACR Oncology Industry Partnership event.
January 2025 – OCE ENGAGE – Project Community
Click to share this newsletter with your friends! Welcome to the January 2025 edition of the FDA Oncology Center of Excellence (OCE) quarterly newsletter from…
SSO President Update: ACT 2025 with Dr. Senthil
Watch this latest SSO President Update featuring Maheswari Senthil, MD, discussing details of the upcoming Advanced Cancer Therapies meeting taking place in …
Bortezomib combined with ibrutinib/rituximab in the first-line treatment of WM
Christian Buske, MD, University Hospital Ulm, Ulm, Germany, discusses findings from the ECWM-2 trial (NCT03620903), which evaluated the combination of ibrutinib, rituximab, and bortezomib for…
Telehealth Continues to Show Importance Post COVID-19 in Rare Diseases
In an interview with Peers & Perspectives in Oncology, Doris M. Ponce, MD, MS, a bone marrow transplant specialist, discussed how telehealth made a significant…
Savolitinib Combo Earns Priority Review in China for EGFR+ NSCLC
Findings from the phase 3 SACHI trial support the National Medical Products Administration’s priority review designation for savolitinib/osimertinib.
How family history knowledge can lead to cancer genetics intervention
Knowledge is power when it comes to family history and cancer risk.
January 2025 – OCE ENGAGE – Project Community
Click to share this newsletter with your friends! Welcome to the January 2025 edition of the FDA Oncology Center of Excellence (OCE) quarterly newsletter from…